Dosimetric comparison of MR-guided adaptive IMRT versus 3DOF-VMAT for prostate stereotactic radiotherapy

被引:1
|
作者
Kong, Vickie C. [1 ,2 ]
Dang, Jennifer [1 ]
Li, Winnie [1 ,2 ]
Navarro, Inmaculada [1 ,2 ]
Padayachee, Jerusha [1 ,2 ]
Malkov, Victor [1 ,2 ]
Winter, Jeff [1 ,2 ]
Raman, Srinivas [1 ,2 ]
Berlin, Alejandro [1 ,2 ]
Catton, Charles [1 ,2 ]
Warde, Padraig [1 ,2 ]
Chung, Peter [1 ,2 ]
机构
[1] Princess Margaret Canc Ctr, Radiat Med Program, Toronto, ON, Canada
[2] Univ Toronto, Dept Radiat Oncol, Toronto, ON, Canada
关键词
MR -guided adaptive radiotherapy; IMRT; VMAT; Prostate SBRT; VOLUMETRIC MODULATED ARC; BODY RADIOTHERAPY; PLAN QUALITY; CANCER; THERAPY; BRACHYTHERAPY;
D O I
10.1016/j.tipsro.2022.02.003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: To compare the dosimetry of prostate stereotactic radiotherapy (SBRT) delivered by adaptive intensity modulated radiotherapy (A-IMRT) and 3 degree of freedom volumetric modulated arc therapy (3DOF VMAT) Methods & Materials: Twenty-five prostate patients treated with High Dose Rate (HDR) brachytherapy followed by SBRT were included (fifteen with hydrogel spacer in place for treatment). Interfraction changes in the volume of prostate, rectum and bladder were measured. Fractional dose to these structures was estimated for A-IMRT and 3DOF-VMAT for comparison against the corresponding reference dose and between each other. Results: Clinically acceptable dose was delivered to prostate in all 125 fractions through A-IMRT and 3DOFVMAT. A-IMRT was better than 3DOF-VMAT in reducing dose to 1 cm3 of rectum. Conversely, 3DOF-VMAT was superior in sparing 50% and 20% of rectum. When comparing the reference and delivered dose, there was no significant difference for Bladder D5cm3 for either technique. However, rectum in the high dose region benefited more from A-IMRT by being irradiated to a lower than reference dose in more fractions than 3DOFVMAT. Hydrogel spacer reduced the rectal dose and was associated with a smaller deviation from reference dose for rectum D50% for A-IMRT. Conclusions: Despite the presence of large interfraction organ volumes changes, clinically acceptable dose was delivered to the prostate by both systems. A-IMRT facilitated a greater rectal sparing from the high dose region than 3DOF-VMAT. Further reduction in rectal dose could be achieved by hydrogel spacer to displace the rectum, or by adaptation delivered by VMAT.
引用
收藏
页码:64 / 70
页数:7
相关论文
共 50 条
  • [1] Dosimetric Analyses of Stereotactic MR-Guided Adaptive Radiotherapy for Kidney Tumors
    Hsu, S.
    Han, Z.
    Sudhyadhom, A.
    Hu, Y.
    Mak, R.
    Huynh, M.
    Van Dams, R.
    Tanguturi, S.
    Venkatachalam, V.
    Cagney, D.
    Leeman, J.
    MEDICAL PHYSICS, 2022, 49 (06) : E762 - E763
  • [2] Feasibility of Stereotactic MR-Guided Adaptive Radiotherapy in Localized Prostate Cancer
    Mustafayev, T. Z.
    Atalar, B.
    Gungor, G.
    Sengoz, M.
    Abacioglu, U.
    Ozyar, E.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E916 - E916
  • [3] Changes in Prostate Volume and Dosimetry with Stereotactic MR-Guided Adaptive Radiotherapy
    Huynh, E.
    Williams, C.
    Han, Z.
    Singer, L.
    Huynh, M.
    Mak, R.
    Cagney, D.
    Leeman, J.
    MEDICAL PHYSICS, 2021, 48 (06)
  • [4] Dosimetric Benefits of Stereotactic MR-guided Adaptive Radiotherapy in Locally Advanced Pancreatic Cancers
    Michalet, M.
    Riou, O.
    Thezenas, S.
    Llacer, C.
    Grapin, M.
    Demontoy, S.
    Valdenaire, S.
    Debuire, P.
    Azria, D.
    Fenoglietto, P.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E332 - E333
  • [5] Long term outcomes of stereotactic MR-guided adaptive radiotherapy for prostate cancer
    van Vliet, Claire
    Meijnen, Philip
    Piet, Anna H. M.
    Cobussen, Paul
    Slotman, Berend J.
    van Moorselaar, Reindert J. A.
    Bruynzeel, Anna M. E.
    RADIOTHERAPY AND ONCOLOGY, 2024, 194 : S2546 - S2548
  • [6] MR-guided stereotactic radiotherapy of abdominal metastases: toxicity and dosimetric predictors
    Felter, Mette V.
    Moller, Pia K.
    Josipovic, Mirjana
    Bekke, Susanne N.
    Bernchou, Uffe
    Serup-Hansen, Eva
    Madsen, Kasper
    Parikh, Parag
    Kim, Joshua
    Geertsen, Poul
    Behrens, Claus P.
    Vogelius, Ivan R.
    Pohl, Mette
    Schytte, Tine
    Persson, Gitte F.
    RADIOTHERAPY AND ONCOLOGY, 2024, 194 : S1996 - S1999
  • [7] A TOXICITY COMPARISON OF STEREOTACTIC BODY RADIOTHERAPY IN LOCALIZED PROSTATE CANCER: 1.5T MR-GUIDED RT VERSUS LINAC- BASED VMAT
    Trapani, Giovanna
    Nicosia, Luca
    Vitale, Claudio
    Cuccia, Francesco
    Rigo, Michele
    Figlia, Vanessa
    Mazzola, Rosario
    Giaj-Levra, Niccolo
    Ricchetti, Francesco
    Ruggeri, Ruggiero
    Alongi, Filippo
    ANTICANCER RESEARCH, 2022, 42 (10) : 5129 - 5130
  • [8] Daily dosimetric variation between image-guided volumetric modulated arc radiotherapy and MR-guided daily adaptive radiotherapy for prostate cancer stereotactic body radiotherapy
    Nicosia, Luca
    Sicignano, Gianluisa
    Rigo, Michele
    Figlia, Vanessa
    Cuccia, Francesco
    De Simone, Antonio
    Giaj-Levra, Niccolo
    Mazzola, Rosario
    Naccarato, Stefania
    Ricchetti, Francesco
    Vitale, Claudio
    Ruggieri, Ruggero
    Alongi, Filippo
    ACTA ONCOLOGICA, 2021, 60 (02) : 215 - 221
  • [9] MR-Guided Adaptive Radiotherapy in Localized Prostate Cancer
    Allegra, Andrea Gaetano
    Nicosia, Luca
    Rigo, Michele
    Bianchi, Nicola
    Borgese, Riccardo Filippo
    De Simone, Antonio
    Giaj-Levra, Niccolo
    Gurrera, Davide
    Naccarato, Stefania
    Pastorello, Edoardo
    Ricchetti, Francesco
    Sicignano, Gianluisa
    Ruggieri, Ruggero
    Alongi, Filippo
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2025, 24
  • [10] MR-guided adaptive versus CT-guided stereotactic radiotherapy for prostate cancer: Where is the best cost-benefit balance?
    Castelluccia, A.
    Marchesano, D.
    Grimaldi, G.
    Annessi, I
    Bianciardi, F.
    Di Palma, A.
    Valentino, M.
    Verna, L.
    Confaloni, V
    Rea, F.
    Tolu, B.
    Borrazzo, C.
    Rago, M.
    Masi, M.
    El Gawhary, R.
    Gentile, P. C.
    EUROPEAN UROLOGY, 2022, 81 : S1412 - S1412